Molitor B, Börgermann C
Klinik für Urologie, onkologische Urologie und Kinderurologie, Krankenhaus Düren, Roonstraße 30, 52351 Düren, Deutschland.
Urologe A. 2012 Mar;51(3):357-62. doi: 10.1007/s00120-011-2758-5.
Every year in Germany approximately 12,000 men die of castration-resistant prostate cancer even though early detection using PSA-based diagnostics allows more patients to be diagnosed with a curable cancer. An established first line therapy at this stadium is docetaxel chemotherapy, given in a 3-week regimen, providing an overall survival advantage of 2 months. In 6-9 months, the patients treated primarily with docetaxel will progress to a docetaxel-insensitive phase which requires a secondary systemic therapy. Increasing understanding of molecular signal transduction has permitted a growing variety of promising modern drugs, including cabazitaxel, sipuleucel-T and abiraterone. More prospective clinical data will provide a large variety of different therapy combinations, sequence therapies or other therapy regimens particularly for selected subgroups of patients with castration-resistant prostate cancer.
在德国，尽管基于前列腺特异抗原（PSA）的诊断方法能使更多患者被诊断出患有可治愈的癌症，但每年仍有大约12,000名男性死于去势抵抗性前列腺癌。在这个阶段，既定的一线治疗方法是多西他赛化疗，采用3周疗程，可使总生存期延长2个月。在6至9个月内，主要接受多西他赛治疗的患者会进展到对多西他赛不敏感的阶段，这就需要进行二线全身治疗。对分子信号转导的认识不断加深，催生了越来越多有前景的现代药物，包括卡巴他赛、 sipuleucel-T和阿比特龙。更多前瞻性临床数据将为去势抵抗性前列腺癌患者的特定亚组提供大量不同的治疗组合、序贯疗法或其他治疗方案。
